Method of early diagnosis of immune-mediated inflammatory disease
AssigneesUniversite De Liege, Centre Hospitalier Universitaire De Liege
InventorsMichel MALAISE, Dominique DE SENY
Life of this patent
Estimating the term…
Abstract
An in-vitro method for early diagnosing or prediction of immune-mediated inflammatory diseases, comprising: —obtaining a sample from a subject; —quantifying simultaneously by one LC/MS-MS analysis of said sample, a presence of V65 vitronectin fragment or fragment, variant or degradation product thereof; and a presence of a complement C3f or fragment or variant or degradation products thereof;
Claims17
An in-vitro method for early diagnosing or prediction of immune-mediated inflammatory diseases, comprising:
- obtaining a biological sample from a subject;
- quantifying simultaneously by one LC/MS-MS analysis of said biological sample, a presence of V65 vitronectin fragment or fragment, variant or degradation product thereof;
- and a presence of a complement C3f or fragment, variant or degradation product thereof;
The method according to any preceding claims, wherein the V65 vitronectin fragment comprises the following amino sequence:
- 381SQRGHSRGRNQNSRRPS397
The method according to any preceding claims wherein the complement C3f comprises the following amino sequence:
- 1304SSKITHRIHWESASLLR1320
The method according to any preceding claims wherein the immune-mediated inflammatory diseases is osteoarthritis.
The method according to any preceding claims wherein the immune-mediated inflammatory diseases is lupus
The method according to any preceding claims wherein the immune-mediated inflammatory diseases is sclerodermia
The method according to any preceding claims wherein the LC/MS-MS analysis is a microfluidic liquid chromatography coupled to a nanoelectrospray source ion trap mass spectrometry analysis.
The method according to any preceding claims comprising the following steps:
- mixing the biological sample with an acidic aqueous solution;
- loading the resulting mixture on a trapping LC column;
- optionally washing the column to remove uncertain component;
- eluting the column with an alcoholic mixture and obtaining an eluate;
- drying the eluate;
- dispersing the dried eluate in an acetonitrile aqueous solution;
- loading the resulting dispersion on a reversed phase LC column and separating two mobile phase A and B;
- injecting by continuous flux in MS-MS, both phases A and B and quantifying V65 vitronectin fragment or fragment, variant or degradation product thereof simultaneously to quantificating complement C3f or fragment, variant or degradation product thereof.
The method according to any preceding claims wherein C3f or fragment, variant or degradation product thereof are quantified at m/z 459.3, 530.7 and 646.3 and wherein V65 vitronectin fragment or fragment, variant or degradation product thereof are quantified at m/z 434.9, 445.2, 460.5, 466.2, 469.7, 480.3, 485.3.
Dependencies are inferred from the claim text.